- Featured Product
- KD/KO Validated
c-Met (N-terminal) Polyclonal antibody
c-Met (N-terminal) Polyclonal Antibody for FC, IHC, WB,ELISA
Cat no : 19971-1-AP
|Positive WB detected in||HeLa cells|
|Positive IHC detected in||human breast cancer tissue, human colon tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive FC detected in||HeLa cells|
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunohistochemistry (IHC)||IHC : 1:50-1:200|
|Sample-dependent, check data in validation data gallery|
19971-1-AP targets c-Met (N-terminal) in WB, IHC, FC,ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Full Name||met proto-oncogene (hepatocyte growth factor receptor)|
|Calculated molecular weight||156 kDa|
|Observed molecular weight||140 kDa, 50 kDa|
|GenBank accession number||NM_000245|
|Gene ID (NCBI)||4233|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
c-Met (also named as MET or HGFR) is a receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. c-Met regulates many physiological processes including proliferation, scattering, morphogenesis and survival. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Overexpression and/or mutation of c-Met has been reported in various human malignancies, including lung cancer, breast cancer, head and neck cancer, gastric cancer, colorectal cancer, bladder cancer, uterine cervix carcinoma, and esophageal carcinoma, c-Met could serve as an important therapeutic target (PMID: 26036285). This antibody recognizes the N-term of c-Met.
Am J Pathol
PIK3CG Is a Potential Therapeutic Target in Androgen Receptor-Indifferent Metastatic Prostate Cancer.
MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1.
A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness.